Endexx Announces Investment in EcoHealth Neuropathy Inc.
September 12 2018 - 7:09AM
InvestorsHub NewsWire
Targeting Multi-Billion-Dollar Market for Pain Relief
Treatment for Diabetic Neuropathy Patients
Cave Creek, AZ -- September 12, 2018 -- InvestorsHub NewsWire --
Endexx Corporation (OTC PINK: EDXC), a provider of innovative
phytonutrient-based food and nutritional products, has announced
its investment in EcoHealth Neuropathy, Inc., an Arizona-based
corporation, to launch its platform for clinical and technology
driven management of neuropathies.
EcoHealth Neuropathy Inc., a full-service healthcare provider
for the treatment of diabetic neuropathy will be led by Dr. Daniel
Kiddy, Endexx's Chief Medical Officer. Dr. Kiddy, will help
build and manage the health practice and design compliance and
standard operating procedures for the utilization of natural
plant-based medicine in the treatment of neuropathy patients.
CEO Todd Davis commented, “Endexx looks to lead the
standardization of government compliance, as well as, collaborate
with state educational institutions in Arizona. We will be
establishing best practices and procedures for plant-based
alternative medicine in support of traditional medical practices.
In addition, podiatric care physicians will be the first targeted
roll-out for the patient treatment, utilizing phyto-nutrients as
alternative medicine. This is a tremendous market opportunity, as
the diabetic neuropathy market is set to reach $5.7 billion by 20
24.”
Dr. Daniel Kiddy stated, “After four years of case study
observation of patients utilizing phyto-cannibidiol for the
reduction of pain, Endexx and EcoHealth Neuropathy will
establishment a scientific platform to conduct clinical trials and
collect data that can be peer evaluated and published over time,
leading to a strong alternative for the treatment of pain and
neuropathy versus opiate based pain management.”
About Endexx
Endexx, with its collaborative partners and consultants,
develops and distributes two consumable product lines derived from
industrial hemp, which is organic and naturally rich in
phytocannabinoids. Phyto-Bites® is its CBD-infused soft chews for
dogs. The dog treats are formulated to promote health and support
the reduction of separation anxiety, pain and inflammation. The
company also has two technology products and services that launched
in 2014 – the m3hub and the AutoSpense™. Both products provide
essential solutions to promote regulatory compliance and full
accountability. The AutoSpense™ is a commercial-grade inventory
control and dispensing device that provides up-to-the-minute
accounting details and ensures both product and patient security.
By automating the dispensing process, AutoSpense™ increases
productivity and reduces costs for marijuana retailers, while
enhancing their service quality by reducing transaction time for
customers. Websites
include: www.cbdunlimited.com, www.endexx.com and www.phytobites.com.
Safe Harbor Notice
This press release may contain “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, such as statements relating to financial results and plans
for future development activities, and are thus prospective.
Forward-looking statements include all statements that are not
statements of historical fact regarding intent, belief or current
expectations of the company, its directors or its officers.
Investors are cautioned that any such forward-looking statements
are not guarantees of future performance and involve risks and
uncertainties, many of which are beyond the company's ability to
control. Actual results may differ materially from those projected
in the forward-looking statements. Among the factors that could
cause actual results to differ materially from those indicated in
the forward-looking statements are risks and uncertainties
associated with the company’s business and finances in general,
including the ability to continue and manage its growth,
competition, global economic conditions and other factors discussed
in detail in the Company’s periodic filings with the Securities and
Exchange Commission. The company undertakes no obligation to update
any forward-looking statements.
Contact: For further investor and media information, contact: Endexx CorporationTodd DavisChairman & CEO endexx@endexx.com 480-595-6900 EcoHealth Neuropathy, Inc. Dr. Daniel Kiddy CMO 636-544-6247
Endexx (PK) (USOTC:EDXC)
Historical Stock Chart
From Dec 2024 to Jan 2025
Endexx (PK) (USOTC:EDXC)
Historical Stock Chart
From Jan 2024 to Jan 2025
